4 reports

Japan United States European Union Therapy Type ## Diabetes Gliptins

  • Clinical Trial
  • Type 2 Diabetes
  • Japan
  • India
  • China
  • United States
  • Drug Approval
  • Prescription Drug Sales

This study covers the latent demand outlook for diabetes drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or...

  • Diabetes
  • India
  • United States
  • Disposable Income
  • Purchasing Power Parity

China India Prescriptions Filled Pharmaceutical Therapy Cardiology Gliptins Calcium Channel Blocker

  • Pharmaceutical
  • China
  • India
  • Brazil
  • Russia
  • Health Expenditure
  • Spending On Medicines

Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Company, Limited have agreed to form a strategic sales alliance to conduct joint sales activities for DPP## inhibitor, MP-##, and SGLT## inhibitor, TA-##, which are under development by Tanabe in Japan for the treatment of type II diabetes mellitus.

  • Pharmaceutical
  • Financial Services
  • Japan
  • United States
  • India
  • Prescription Drug Sales
  • Cosmetics Revenue